Product Introduction:
Oxa 100mg contains Oxaliplatin, a third-generation platinum-based cytotoxic agent. It is primarily indicated for advanced colorectal cancer, often used in combination with 5-Fluorouracil (5-FU) and Leucovorin as part of the FOLFOX regimen. This injectable formulation is administered intravenously under the supervision of oncology professionals.
Uses:
Oxa 100mg is commonly used for:
-
Metastatic colorectal cancer
-
Adjuvant treatment of stage III colon cancer after complete resection
-
In combination with 5-FU and Leucovorin (FOLFOX protocol)
-
As part of combination regimens in other gastrointestinal cancers (as per physician guidance)
-
Off-label uses in pancreatic, gastric, or esophageal cancers in specific clinical scenarios
Storage Instructions:
-
Store between 2°C to 8°C (Refrigerated)
-
Do not freeze
-
Protect from light and heat
-
Once diluted, use the solution within specified timeframe (as per product label and hospital policy)
-
Keep out of reach of children
How It Works (Mechanism of Action):
Oxaliplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription. This leads to DNA damage and eventually cell death, particularly in rapidly dividing cancer cells. It exhibits cytotoxic effects by inhibiting DNA synthesis and repair, thereby controlling tumor growth.
Side Effects:
Common side effects include:
-
Nausea and vomiting
-
Diarrhea or constipation
-
Fatigue
-
Peripheral neuropathy (numbness, tingling in hands/feet)
-
Low blood cell counts (anemia, leukopenia, thrombocytopenia)
-
Mouth sores
Serious side effects may include:
-
Severe allergic reactions (bronchospasm, rash, hypotension)
-
Pulmonary toxicity
-
Hepatotoxicity
-
Severe peripheral sensory neuropathy
-
Renal dysfunction (rare)
Dosage (Typical Recommended Dose):
-
Standard dose: 85 mg/m² every 2 weeks, administered via IV infusion over 2 hours, often in combination with 5-FU and Leucovorin
-
Dose adjustments may be necessary based on toxicity, renal function, or blood counts
-
The actual dose is calculated based on body surface area (BSA)
Method of Administration:
-
Administered via intravenous infusion
-
Dilute in 5% Dextrose before administration (not compatible with saline)
-
Should be administered by trained oncology healthcare professionals
-
Pre-medication for nausea (antiemetics) may be required before infusion
Precautions:
-
Avoid cold exposure (cold drinks, cold weather) after treatment to reduce risk of acute neuropathy
-
Monitor complete blood counts (CBC), renal, and hepatic functions regularly
-
Inform your doctor if you experience tingling or numbness, which can become persistent
-
Use with caution in patients with renal impairment
-
Not recommended during pregnancy or breastfeeding
-
Ensure adequate hydration before and after infusion
Drug Interactions:
-
Increased risk of toxicity with other neurotoxic agents (e.g., cisplatin, paclitaxel)
-
May alter the effectiveness of live vaccines – avoid vaccination during treatment
-
Caution when used with drugs that cause myelosuppression or nephrotoxicity
-
Always inform your doctor of all medications, including over-the-counter drugs and supplements
Allergies:
-
Contraindicated in patients with a known hypersensitivity to Oxaliplatin or other platinum-containing compounds
-
Allergic reactions may occur during infusion — signs include difficulty breathing, rash, or facial swelling
-
Emergency care is required if signs of anaphylaxis occur
Overdose Information:
-
Overdose may cause severe bone marrow suppression, neurotoxicity, and GI toxicity
-
There is no specific antidote; treatment is symptomatic and supportive
-
Seek immediate emergency care if overdose is suspected
Missed Dose Instructions:
-
If a dose is missed, contact your oncologist immediately
-
The next treatment session should be rescheduled according to your medical team’s guidance
-
Do not self-adjust or delay chemotherapy doses without professional advice
Additional Notes:
-
Peripheral neuropathy may be triggered or worsened by cold, so avoid cold exposure after infusion
-
Patients often receive antiemetics to prevent nausea and vomiting
-
May require dose reduction or delay in case of severe side effects or lab abnormalities
-
Treatment often lasts for 6–12 cycles, depending on cancer stage and response
-
Report any unusual bleeding, persistent fever, or signs of infection promptly
